Circulating tumor DNA-From bench to bedside.
MetadataShow full item record
In the era of personalized medicine, tumor sampling is paramount to enable the assessment of actionable molecular aberrations to help rationalize and guide treatment decisions. Longitudinal tracking of such aberrations may also be helpful to detect emerging drug resistance and to allow for timely modifications to ongoing therapies to improve patient outcomes. Nevertheless, tumor tissue sampling involves an invasive procedure with potential risks to patients and involves logistical challenges. As such, other less invasive and safer methods such as blood sampling for molecular profiling has been gaining traction. In this article, we discuss the concept of circulating tumor DNA, the technology platforms available for its interrogation, and its current applications in the clinic. We also envision how circulating tumor DNA may be applied at multiple time points along a patient's cancer journey to guide diagnosis, prognostication, and therapeutic decisions.
Version of record
Circulating tumor DNA (ctDNA)
Circulating Tumor DNA
DNA Mutational Analysis
Early Detection of Cancer
Gene Expression Profiling
High-Throughput Nucleotide Sequencing
Polymerase Chain Reaction
Sequence Analysis, DNA
United States Food and Drug Administration
Medicine Drug Development Unit (de Bono)
License start date
Curr Probl Cancer, 2017, 41 (3), pp. 212 - 221